Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Shanghai Pulmonary Hospital, Shanghai, China appears in 145 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownT2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPDNCT07823842 · lead sponsor · 2026-07-30
RECRUITINGOral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLCNCT07754812 · lead sponsor · 2026-06-25
RECRUITINGNeoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLCNCT07863999 · lead sponsor · 2026-05-01
RECRUITINGEfficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung CancerNCT07410975 · lead sponsor · 2026-01-10
RECRUITINGIBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung CancerNCT07408635 · lead sponsor · 2026-01-07
RECRUITINGNeoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung CancerNCT07323056 · lead sponsor · 2026-01-01
RECRUITINGSynthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter StudyNCT07243873 · lead sponsor · 2025-12-01
RECRUITINGThoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride BupivacaineNCT07134660 · lead sponsor · 2025-09-01
RECRUITINGNeoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer PatientsNCT06987734 · lead sponsor · 2025-06-19
RECRUITINGPost-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung CancerNCT06758700 · lead sponsor · 2025-02-07
RECRUITINGAn Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line SettingNCT06749886 · lead sponsor · 2024-11-19
RECRUITINGWSI Based DL for Diagnosing the IASLC Grading System of Lung AdenocarcinomaNCT05925764 · lead sponsor · 2024-10-15
RECRUITINGA Study on the Efficacy of Atezolizumab Combined with ChemotherapyNCT06780826 · lead sponsor · 2024-08-28
RECRUITINGAdjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung AdenocarcinomaNCT06528847 · lead sponsor · 2024-06-05
RECRUITINGNeoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 TrialNCT06256237 · lead sponsor · 2024-04-01
RECRUITINGDisitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expressionNCT06749860 · lead sponsor · 2024-02-02
RECRUITINGExploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world StudyNCT06216782 · lead sponsor · 2023-12-16
RECRUITINGPatient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung CancerNCT07328945 · lead sponsor · 2023-12-01
RECRUITINGExploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung CancerNCT05965024 · lead sponsor · 2023-10-25
RECRUITINGExploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor EnvironmentNCT05857800 · lead sponsor · 2023-05-25
RECRUITINGInduction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung CancerNCT05766800 · lead sponsor · 2023-03-14
RECRUITINGNeoadjuvant Immunotherapy for Stage III Non-small Cell Lung CancerNCT04728724 · lead sponsor · 2022-09-10
RECRUITINGNeoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung AdenocarcinomaNCT05503667 · lead sponsor · 2022-02-01
RECRUITINGEfficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical TrialNCT05053802 · lead sponsor · 2021-03-21
RECRUITINGPD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung CancerNCT04539977 · lead sponsor · 2020-09-01
RECRUITINGSegmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cmNCT04937283 · lead sponsor · 2019-10-01
RECRUITINGComparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cmNCT05838053 · lead sponsor · 2019-08-20
RECRUITINGSurgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%NCT03351842 · lead sponsor · 2017-09-01
RECRUITINGOral Paclitaxel as Neoadjuvant Therapy in Elderly NSCLC: A Phase II TrialNCT07599163 · lead sponsor · 2026-06-08
NOT_YET_RECRUITINGNeoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.NCT07608159 · lead sponsor · 2026-05-01
NOT_YET_RECRUITINGApplication of Electromagnetic Navigation System in Pulmonary Nodule LocalizationNCT07595120 · lead sponsor · 2026-05-01
NOT_YET_RECRUITINGA Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based RegimensNCT07469488 · lead sponsor · 2026-04-30
NOT_YET_RECRUITINGNab-Paclitaxel Combined With Local Therapy in Relapsed SCLCNCT07547332 · lead sponsor · 2026-04-06
NOT_YET_RECRUITINGCombining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II TrialNCT07517640 · lead sponsor · 2026-04-01
NOT_YET_RECRUITINGStudy on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer PatientsNCT07493980 · lead sponsor · 2026-03-01
NOT_YET_RECRUITINGA Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational StudyNCT07375979 · lead sponsor · 2026-02-05
NOT_YET_RECRUITINGEnsartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLCNCT07235306 · lead sponsor · 2025-12-01
NOT_YET_RECRUITINGSegmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCTNCT07169903 · lead sponsor · 2025-10-01
NOT_YET_RECRUITINGBozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung CancerNCT07153770 · lead sponsor · 2025-09-20
NOT_YET_RECRUITINGA Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer TherapyNCT07101627 · lead sponsor · 2025-08-01
NOT_YET_RECRUITINGToripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033NCT07097948 · lead sponsor · 2025-08-01
NOT_YET_RECRUITINGPredictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung CancerNCT06895941 · lead sponsor · 2025-04-30
WITHDRAWNComparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical StudyNCT06946836 · lead sponsor · 2025-04-21
NOT_YET_RECRUITINGNeoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLCNCT06837948 · lead sponsor · 2025-02-18
NOT_YET_RECRUITINGThe Effect of Semi-recumbent Position on Hypoxemia After Lung Segment/Lobe SurgeryNCT07060625 · lead sponsor · 2024-12-23
ENROLLING_BY_INVITATIONVebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)NCT06644313 · lead sponsor · 2024-11-01
NOT_YET_RECRUITINGToripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung CancerNCT06648200 · lead sponsor · 2024-11-01
NOT_YET_RECRUITINGThe Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world StudyNCT06652555 · lead sponsor · 2024-10-30
NOT_YET_RECRUITINGNeoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.NCT07274761 · lead sponsor · 2024-10-17
ACTIVE_NOT_RECRUITINGThe Impact of Communication With Healthcare Providers Via WeChat on Survival Outcomes for Lung Cancer PatietnsNCT06592430 · lead sponsor · 2024-10-01
UNKNOWNA Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLCNCT06585644 · lead sponsor · 2024-10-01
NOT_YET_RECRUITINGA Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung CancerNCT06620796 · lead sponsor · 2024-09-30
NOT_YET_RECRUITINGEfficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical TrialNCT06620822 · lead sponsor · 2024-09-30
NOT_YET_RECRUITINGInduction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung CancerNCT06591910 · lead sponsor · 2024-09-20
NOT_YET_RECRUITINGA Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung CancerNCT06530797 · lead sponsor · 2024-08-01
UNKNOWNPhase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung CancerNCT06463171 · lead sponsor · 2024-06-01
UNKNOWNToripalimab Combined With SBRT for NSCLCNCT06293690 · lead sponsor · 2024-04-15
ACTIVE_NOT_RECRUITINGNeoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory TrialNCT06282536 · lead sponsor · 2024-03-01
NOT_YET_RECRUITINGLM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06479759 · lead sponsor · 2024-01-12
UNKNOWNPerioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung CancerNCT06109402 · lead sponsor · 2023-12-20
NOT_YET_RECRUITINGDrugs studied in this sponsor's trials
23 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing Shanghai Pulmonary Hospital, Shanghai, China as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
carboplatin8
toripalimab7
placebo6
etoposide5
paclitaxel protein-bound5
erlotinib3
pemetrexed3
platinum3
carboplatin RxCUI 40048 · Lead sponsor in 8 linked trial(s) · 3 currently recruiting
8 trials
toripalimab RxCUI 2669406 · Lead sponsor in 7 linked trial(s) · 1 currently recruiting
7 trials
placebo RxCUI 8375 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
6 trials
etoposide RxCUI 4179 · Lead sponsor in 5 linked trial(s) · 2 currently recruiting
5 trials
paclitaxel protein-bound RxCUI 486610 · Lead sponsor in 5 linked trial(s) · 2 currently recruiting
5 trials
erlotinib RxCUI 337525 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
3 trials
pemetrexed RxCUI 68446 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting
3 trials
platinum RxCUI 1311280 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting
3 trials
ambrisentan RxCUI 358274 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting
2 trials
atezolizumab RxCUI 1792776 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting
2 trials
gefitinib RxCUI 328134 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
2 trials
simvastatin RxCUI 36567 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting
2 trials
afatinib RxCUI 1430438 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
bevacizumab RxCUI 253337 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
denosumab RxCUI 993449 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
gemcitabine RxCUI 12574 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
irinotecan RxCUI 51499 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
Spiriva RxCUI 274535 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
sunvozertinib RxCUI 2719226 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
Symbicort RxCUI 327148 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
tadalafil RxCUI 358263 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting
1 trial
tislelizumab RxCUI 2677426 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
Sponsor roles
lead sponsor104
collaborator41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.